Methods of inhibiting leukotriene A4 hydrolase
US10898471B2 · kind B2 · utility
0Cited by
48References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 17, 2019 |
| Grant date | Jan 26, 2021 |
| Priority date | — |
| Expiry date | Jun 17, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.